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Abstract.
Background: There are only few population-based studies that have systemically investigated the prevalence of hippocampal
sclerosis (HS) in the very old. The frequency of unilateral versus bilateral HS has been rarely studied.
Objective: We investigated the prevalence and laterality of HS and its association with other neurodegenerative and vascular
pathologies in a population-based sample of very elderly. Furthermore, the concomitant presence of immunoreactivity for
TDP-43, p62, and HPtau was studied.
Methods: The population-based Vantaa 85+ study includes all inhabitants of the city of Vantaa, who were >85 years in 1991
(n = 601). Neuropathological assessment was possible in 302 subjects. Severity of neuronal loss of CA sectors and subiculum
was determined bilaterally by HE- staining. Immunohistochemistry performed using antibodies for TDP-43, p62, and HPtau.
Results: Neuronal loss and pathological changes in the hippocampus sector CA1 and subiculum were observed in 47 of the
302 individuals (16%), and 51% of these changes were bilateral. HS without comorbid neurodegenerative pathology was
found in 1/47 subjects with HS (2%). Dementia (p < 0.001) and TDP-43 immunopositivity of the granular cell layer of the
dentate fascia (p < 0.001) were strongly associated with HS. The CERAD score, immunopositivity for HPtau and p62 in the
granular cell layer of the fascia dentate were also associated.
Conclusion: HS is prevalent (16%) in the oldest old population, but HS without any comorbid neurodegenerative pathology
is rare. The high frequency of unilateral HS (49%) implied that bilateral sampling of hippocampi should be routine practice
in neuropathological examination.
Keywords: Dementia, hippocampal sclerosis, hippocampal sclerosis without any comorbid neurodegenerative pathology,
laterality, population-based, TDP-43, very old
INTRODUCTION
The term hippocampal sclerosis (HS) [1–11]
is commonly used to refer to old age-associated
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brain disease with neuronal loss and gliosis in the
hippocampal formation that is out of proportion
to AD-type pathology [12–17] and often associ-
ated with TDP-43 (Transactive response binding
protein-43) pathology [18–28]. Typical clinical pre-
sentation shows cognitive and functional impairment
[7, 28–31], and HS can be difficult to distinguish,
especially from late-onset Alzheimer’s disease (AD)
[1, 15, 24, 32–35]. Frequently, HS occurs with other
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age-related neurodegenerative pathologies, and it
occurs only rarely without any comorbid pathology
[23, 31, 36–40]. Definitions of HS have traditionally
varied [20, 23], which complicates comparison of HS
studies.
The reported prevalence of HS in aged popula-
tions is variable, ranging from 2.8% to over 20%
[4, 6, 7, 10, 11, 29, 30, 34]. A recent meta-analysis,
largely confined to hospital-based materials, reported
the oldest old to have a peak in incidence of HS
after the age of 95 years [7, 17]. However, there
are only few population/community-based studies
[20, 30] where the prevalence of HS can be reliably
investigated. Furthermore, only few studies have sys-
tematically investigated whether the loss of neurons
appears bilaterally or unilaterally [11, 30].
In this study we sought to address the follow-
ing questions: 1) The prevalence of HS in our
unique population based study material (Vantaa 85+
study, all the individuals aged 85 years or over);
2) The frequency of uni- versus bilateral HS; 3)
The frequency of HS subjects without any comorbid
pathology (absence of apparent other neurodegen-
erative or vascular disease); 4) The association
of HS with other neurodegenerative and vascular




Subjects and clinical examination
The Vantaa 85+ study includes all individuals aged
≥85 years, who were living in the city of Vantaa
(Southern Finland) as of 1 April 1991 (N = 601).
Clinical examination was possible in 553 subjects,
and autopsies were carried out in 302/553 subjects
(55%). Informed consent for the study was requested
from the individuals and/or their close relatives. The
approval for the study was admitted by the Ethics
Committee of Health Center City of Vantaa. Han-
dling of the health and social work data as well
the death certificates was approved by the Finnish
Health and Social Ministry. The National Author-
ity for Medico Legal Affairs (VALVIRA) accepted
the autopsy tissue sample collection and usage for
research purposes. Dementia was diagnosed as part
of the clinical examination according to the DSMIIIR
criteria. The clinical examinations were performed in
1991, 1994, 1996, 1999, and 2001.
Tissue samples
Originally, for the previously reported study on
AD [44], hippocampal samples were obtained after
at least two weeks formalin-fixation from the right
cerebral hemisphere at the level of the lateral genic-
ulate body, and embedded in polyethylene glycol
(PEG). Those tissue blocks were re-processed to
paraffin for this study. First, a vast majority of PEG
matrix was removed manually, after that the blocks
were immersed for 2 min in distilled water. The
blocks were kept in neutral buffered formalin O/N at
room temperature to make sure that PEG was totally
removed. Finally, the blocks were processed in tis-
sue processor (Thermo Shandon Excelsior, Thermo
Fisher, USA), and embedded into paraffin.
For bilateral assessment of the hippocampal
pathology, also the left hippocampus was sampled
after several years of formalin-fixation, and embed-
ded in paraffin. The bilateral tissue sections of
6 m, stained for standard HE, were used for esti-
mation of general histopathological findings and
stage of neuronal loss in each field of the hip-
pocampus. Our standard sampling and assessment
protocols to define pathologies related to AD, Lewy
body disease, macroscopic brain infarcts and cerebral
amyloid angiopathy have been described previously
[41–44]. Braak staging of neurofibrillary degenera-
tion was based on Gallyas stained slides as reported
before [44]. Assessment of Lewy body pathology
was based on immunopositivity of Lewy bodies
and neurites (-synuclein, clone 42, Transduction
Laboratories, USA) as described previously [43].
The assessment of vascular pathology [42] and
a standardized neuropathology protocol for neu-
ritic plaque score, CERAD [44], has been reported
previously. The diagnosis of capillary amyloid-
was determined using Congo red and confirmed
by amyloid- immunohistochemistry (amyloid-,




HS and hemispheric symmetry/asymmetry was
determined on HE- staining by estimating the severity
of neuronal loss. The density of neurons was assessed
semi-quantitatively by three observers MK, LM and
AP using a multi-viewer microscope. The criterion
for HS was based on discussions of the observers
and the earlier publication of Rauramaa et al. [25].
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The extent of neuronal loss was categorized into three
subdivisions.
I. Intact/Infrequent; no sign or minor loss of
pyramidal neurons in the CA1 and subiculum
II. Frequent; severe marked loss of pyramidal
neurons in the CA1 and subiculum
III. Complete; total loss of pyramidal neurons in
the CA1 and subiculum
The subjects fulfilling the criteria for the subdi-
vision I were included in the non-HS group in the
statistical analyses.
The subjects fulfilling the criteria for the subdivi-
sions II and III were included in the HS group in the
statistical analyses.
Immunohistochemistry
The right sided hippocampus tissue blocks were
cut into 4 m thick sections and stained with the
immunostainer LabVision. For the antibodies (p62
[45], TDP-43, and HPtau) we had to use stronger
pretreatment conditions, prolonged incubations times
and more sensitive detection kits compared to routine
samples, due to the high age of the PEG-embedded
tissues. The intense pretreatments and staining con-
ditions caused artefactual staining of lipofuscin in
some of the samples. However, the intensity and
color of lipofuscin pigment (yellowish) was easily
separated from the specific immunopositivity (dark
brown) (Fig. 1). The polymer- based detection kits
were used for detection. All the immunoreactions
were visualized using DAB. More detailed informa-
tion on immunohistochemical stainings is presented
in Table 1. The presence of any specific TDP-43,
p62, and HPtau immunopositivity was noted in gran-
ular cell layer and in pyramidal cell sectors CA4,
CA3, CA2, CA1, and subiculum. The results were
ascertained in consensus sessions by three observers
(MK, LM, and AP). We used p62- IHC- staining as a
confirmatory staining, in order to replicate true neu-
ropathological findings, such as TDP-43 positivity
and, on the other hand, to identify other accompany-
ing pathology.
Statistical analyses
Statistical analyses (Tables 2 and 3) were per-
formed using IBM SPSS Statistics version 22.0. The
Chi-Square test was used to compare the differences
of sex in individuals with and without HS, and with
and without TDP-43 granular cell layer positivity.
The Mann-Whitney U test was used to compare age
at death in these groups. All the other analyses were
performed using binary logistic regression, adjusted
for age at death and sex.
RESULTS
Hippocampi of both hemispheres were analyzed
in all subjects of this population-based cohort. 47 of
302 (15.6%) subjects had severe (subdivision II) or
complete loss of neurons (subdivision III) of the CA1
sector and subiculum, defined as HS (Table 2). There
were 31 subjects in the subdivision II and 16 subjects
in the subdivision III. Of those 47 subjects, bilateral
changes were observed in 51.1%. Unilateral changes
were seen in 23/47 subjects with HS, and unilateral
Fig. 1. A) Hippocampal sclerosis, severe neuronal loss in CA1 sector, HE- stained. B) TDP-43 immunostaining of dentate fascia granule
cells showing NCIs, (open arrow head), dark brown. Lipofuscin (star) is seen as yellowish granular deposits.
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∗General steps for all used antibodies during IHC- staining: 1. Endogenous peroxidase activity was blocked by REALTM Peroxidase-Blocking
Solution (Dako, S2023, Glostrup, Denmark). 2. Immunoreactions were visualised with DAB (3, 3´-diaminobenzidine tetra- hydrochloride)
(Dako, K5007, Agilent, USA). 3. Counterstaining (Mayer´s hematoxylin, S330930-2, Agilent, USA) was performed with slide staining
instrument SAKURA TISSUE-TEK® PRISMA (Sakura Finetek Europe B.V., The Netherlands).
Table 2
Description of all study subjects, and subjects with and without hippocampal sclerosis. Results of association analyses with different variables
Variable All study subjects Non-Hippocampal Hippocampal sclerosis p-value
sclerosis subjects subjects
Number of subjects 302 255 47
Sex
Female/Male 250 (82.8)/52 (17.2) 208 (81.6)/47 (18.4) 42 (89.4)/5 (10.6) NS
Age at death
Mean 92.35 92.18 93.22 NS
Range 85.12–105.64 85.52–105.64 85.12–104.77
Dementia status
Demented/non-demented 195 (64.6)/107(35.4) 150 (58.8)/105 (41.2) 45 (95.7)/2 (4.3) <0.001∗
Demented: Female/Male 165 (84.6)/30(15.4) 124 (82.7)/26 (17.3) 41 (91.1)/4(8.9) NS
CERADi 0.01< p ≤ 0.05∗∗
None 71 (23.5) 65 (25.5) 6 (12.8)
Sparse 33 (10.9) 27 (10.6) 6 (12.8)
Moderate 160 (53.0) 136 (53.3) 24 (51.1)




0-II 89 (29.5) 73 (28.7) 16 (34.0)
III-IV 141 (46.7) 125 (49.0) 16 (34.0)




None 193 (63.9) 165 (64.7) 28 (59.6)
Brain Stem 8 (2.6) 5 (2.0) 3 (6.4)
Limbic 54 (17.9) 48 (18.8) 6 (12.8)
Neocortical 47 (15.6) 37 (14.5) 10 (21.3)
Infarct (location)
Any 162 (53.6) 132 (51.8) 30 (63.8) NS
Heart 119 (41.2) 95 (38.8) 24 (54.5) 0.01< p ≤ 0.05∗∗
Small cortical 57 (18.8) 46 (18.1) 11 (23.4) NS
Large cortical 51 (16.9) 46 (18.0) 5 (10.6) NS
Small white matter 44 (14.6) 34 (13.4) 10 (21.4) NS
Large white matter 6 (2.0) 6 (2.4) 0 (0) NS
(Continued)
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Table 2
(Continued)
Variable All study subjects Non-Hippocampal Hippocampal sclerosis p-value
sclerosis subjects subjects
Small basal ganglia 60 (19.8) 49 (19.2) 11 (23.4) NS
Large basal ganglia 1 (0.3) 1 (0.4) 0 (0) NS
Small brain stem 13 (4.3) 8 (3.1) 5 (10.6) NA
Large brain stem (0.3)1 1 (0.4) 0 (0) NS
Small cerebellum 53 (17.6) 43 (16.9) 10 (21.2) NS
Large cerebellum 15 (4.9) 12 (4.7) 3 (6.4) NS
Anterior circulation 121 (40.1) 100 (39.2) 21 (44.7) NS
Posterior circulation 98 (32.5) 77 (30.2) 21 (44.7) NS
Other vascular variables
Cerebral amyloid angiopathy (all six brain regions)
iv
103(34.1) 91(35.7) 12(25.5) NS
Atherosclerosis in the circle of Willis
v
271 (90.0) 223 (95.3) 48 (100) NS
Coronary disease
vi




CA4 1 (0.4) 3 (6.4) 4 (1.3) NA
CA3-CA2 3 (1.0) 1 (0.4) 2 (4.3) NA
CA1 + Subiculum 98 (32.5) 63 (24.7) 35 (74.5) <0.001∗
GCL 68 (22.5) 33 (12.9) 35 (74.5) <0.001∗
p62
viii
CA4-CA1-Subiculum 173 (57.7) 144 (56.9) 29 (61.7) NS
GCL 99 (33.0) 62 (24.5) 37 (78.7) <0.001∗
Tau
ix
CA4-CA1-Subiculum 274 (91.3) 229 (90.5) 45 (95.7) NS
GCL 167 (55.7) 125 (49.4) 42 (89.4) <0.001∗
NS, no statistical significance. NA, not applicable, N too low for descriptive statistical analysis. ∗p- values <0.001, strong statistical signifi-
cance. ∗∗0.01 < p ≤ 0.05, weak statistical significance.
iA standardized neuropathology protocol for neuritic plaque score developed by the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) [14].
iiCriteria utilized, previously published [12, 44], a staging scheme for neurofibrillary tangles (NFTs) described by Braak and Braak which
encloses six stages: no NFTs, Braak stages I/II with NFTs predominantly in entorhinal cortex and closely related areas, stages III/IV with
NFTs more abundant in hippocampus and amygdala while extending slightly into association cortex, and stages V/VI with NFTs widely
distributed throughout the neocortex and also involving primary motor and sensory areas.
iiiThe third CDLB guidelines for diagnosis of Lewy- body Dementia with modified criteria. The load of Lewy- related pathology (LRP)
was semiquantitatively scored mild, moderate, severe and very severe and followed by the assignment of the type of LRP (none, brainstem-
predominant, limbic and diffuse neocortical), [43].
ivThe diagnosis of capillary amyloid- was determined using Congo red and confirmed by A immunohistochemistry, both analyzed in six
brain areas. The severity of capillary A was graded semi-quantitatively, and the severity of CAA was based on the percentage of affected
vessels [41].
vThe arteries of circulus Willis were inspected and opened at autopsy, and the degree of atherosclerosis was estimated based upon severity
of obstruction in artery. The classification was subdivided into four categories: none, mild, moderate and severe.
viLeft anterior descending, left circumflex and right coronary arteries were dissected at autopsy. The degree of coronary atherosclerosis was
estimated by the pathologist, and scored into four categories: none, mild, moderate and severe [42].
viiThe presence of TDP-43 immunoreactivity were assessed in the regions CA1 and subiculum, CA2, CA3-CA4 and granular layer of dentate
gyrus. TDP-43 immunoreactivity was determined as positive when NCIs seen in the granular cell layer and CA1 + subiculum.
viiip62 immunoreactivity was scored as positive if seen positive NCIs in the granular cell layer of the dentate gyrus [45].
ixTau immunoreactivity was recorded mainly as neurofibrillary lesions and neuropil threads in the granular cell layer of the dentate gyrus,
sectors CA1-CA4 and subiculum.
changes were more common in the left than in the
right hemisphere. On both sides, degree of neuronal
loss in the CA1 sector was more severe compared
to that in the subiculum (more severe changes in the
CA1 sector were seen in 88% of the sections from
the right side, and in 84% of the sections from the
left side). Only one subject (1/47) was found to have
HS without any other significant neurodegenerative
pathology. This subject had severe bilateral neu-
ronal loss in CA1 and subiculum and robust TDP-43
immunopositivity in the granular cell layer of the
dentate fascia (Fig. 1).
The majority of the subjects with HS were women
(89.4%), but there was no statistical evidence for an
association between HS and sex (Table 2). Over-
all, the subjects with HS were older at the time
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of death (on average 12 months), even though this
difference was not statistically significant (p > 0.05)
(Table 2). 45 (95.7%) of the 47 subjects with HS were
demented (p < 0.001) (Table 2). The CERAD score
was weakly associated with HS (0.01< p ≤ 0.05),
whereas neither Braak stage nor Lewy related
pathology showed any association (Table 2). When
frequencies of infarcts in different locations were
compared in subjects with and without HS, an asso-
ciation was seen with heart infarct, 0.01< p ≤ 0.05
(Table 2).
HS was strongly associated with TDP-43 positive
neuronal cytoplasmic inclusions (NCI) in the gran-
ular cell layer of fascia dentate, p < 0.001 (Table 2).
A strong association with TDP-43 positive findings
in the sectors CA1 and subiculum was also found
(Table 2). In the CA1- sectors and subiculum,
TDP-43 staining showed some neuronal cytoplas-
mic inclusions (NCI) and a few neuronal intranuclear
inclusions (NII) (in residual neurons). In addition,
short dystrophic neurites, neuropil threads, and rarely
in some cases, faintly labelled neurofibrillary tangle-
like changes were seen. There was variation in the fre-
quencies found among the TDP-43 deposits in CA1
and subiculum in the HS samples. Tau pathology was
recorded mainly as neurofibrillary lesions and neu-
ropil threads. Interestingly, HPtau immunopositivity
of the granular cell layer was strongly associated with
HS, p < 0.001 (Table 2). Not surprisingly, the same
applied to p62-positive NCI aggregates, p < 0.001,
(Table 2).
As the TDP-43 positivity in the granular cell
layer of the hippocampus has been suggested to be
an early marker of HS [23], we also analyzed all
the variables listed above comparing subjects with
immunopositivity of TDP-43 in the granular cell
layer and those without this kind of immunopositivity
(Table 3). These analyses showed a strongly signifi-
cant association (p < 0.001) with dementia, CERAD
score, p62 and HPtau positivity in granular cell layer.
The following variables showed more modest asso-
ciation (0.01<p ≤ 0.05): age at death, Braak stage,
-synuclein pathology and infarcts in the area of
posterior circulation.
DISCUSSION
In this population-based study on subjects > 85
years old, we found that 1) prevalence of HS was
16%, thus representing one of the most frequent neu-
ropathologies in this age group. 2) Almost a half
(49%) of subjects with HS showed unilateral disease.
3) Only 2% of subjects with HS did not show any
other neurodegenerative pathology, suggesting that
HS without any comorbid pathology is rare. 4) HS
was strongly associated with dementia, immunopos-
Table 3
TDP-43 immunopositivity in the granular cell layer. Results of association analyses with different variables
Variable All study subjects TDP-43GCL- TDP-43GCL- p-value
immunonegative subjects immunopositive subjects
Number of subjects 302 234 68
Gender
Female/Male 250 (82.8)/52(17.2) 191(81.6)/43(18.4) 59(86.8)/9(13.2) NS
Age at death
Mean 92.35 92.09 93.23 0.01 < p ≤ 0.05∗∗
Range 85.12-105.64 85.12-105.64 86.61-103.02
Dementia status
Demented/non-demented 195 (64.6)/107(35.4) 135 (57.7)/99(42.3) 60 (88.2)/8(11.8) <0.001∗
Demented: Female/Male 165(84.6)/30(15.4) 112 (83) /23(17) 53 (88.3)/7(11.7) NS
CERADi <0.001∗
None 71 (23.5) 64 (27.4) 7 (10.3)
Sparse 33 (10.9) 26(11.1) 7 (10.3)
Moderate 160 (53.0) 124(53.0) 36(52.9)
Frequent 38(12.6) 20(8.5) 18(26.5)
BRAAKii 0.01 < p ≤ 0.05∗∗
0-II 89 (29.5) 71 (30.3) 18 (26.5)
III-IV 141 (46.7) 115 (49.1) 26 (38.2)
V-VI 72 (23.8) 48 (20.5) 24 (35.3)
- synucleiniii 0.01 < p ≤ 0.05∗∗
None 193 (63.9) 155 (66.2) 38 (55.9)
Brain Stem 8 (2.6) 5 (2.1) 3 (4.4)
Limbic 54 (17.9) 44 (18.8) 10 (14.7)
Neocortical 47 (15.6) 30 (12.8) 17 (25.0)
(Continued)
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Table 3
(Continued)
Variable All study subjects TDP-43GCL- TDP-43GCL- p-value
immunonegative subjects immunopositive subjects
Infarct (location)
Non-selected 162 (53.6) 121 (51.7) 41 (60.3) NS
Heart 119 (41.2) 92 (40.7) 27 (42.9) NS
Small cortical 57 (18.9) 42 (17.9) 15 (22.1) NS
Large cortical 51 (16.9) 45 (19.2) 6 (8.8) NS
Small white matter 44 (14.7) 34 (14.5) 10 (14.7) NS
Large white matter 6 (2.0) 4 (1.7) 2 (2.9) NS
Small basal ganglia 60 (19.8) 44 (18.8) 16 (23.5) NS
Large basal ganglia 1 (0.3) 0 (0) 1 (1.5) NS
Small brain stem 13 (4.3) 9 (3.8) 4 (5.9) NS
Large brain stem 1 (0.3) 1 (0.4) 0 (0) NS
Small cerebellum 53 (17.5) 38 (16.2) 15 (22.1) NS
Large cerebellum 15 (5.0) 11 (4.7) 4 (5.9) NS
Anterior circulation 121 (40.0) 93 (39.7) 28 (41.2) NS
Posterior circulation 98 (32.5) 69 (29.5) 29 (42.6) 0.01 < p ≤ 0.05∗∗
Other vascular variables
Cerebral amyloid angiopathy 199(65.9) 148(63.2) 51(68.0) NS
(all six brain regions) iv
Atherosclerosis in the circle of Willisv 271 (90.0) 211 (95.5) 60 (98.4) NS
Coronary diseasevi 232 (80.3) 178 (78.8) 54 (85.7) NS
Immunopositivity
p62viii
CA4-CA1-Subiculum 173 (57.7) 134 (57.5) 39 (58.2) NS
GCL 99 (33.0) 43 (18.5) 56 (83.6) <0.001∗
Tauix
CA4-CA1-Subiculum 274 (91.3) 211 (47.6) 63 (94.0) NS
GCL 167 (55.7) 111 (47.6) 56 (83.6) <0.001∗
NS, no statistical significance. NA, not applicable, N too low for descriptive statistical analysis.∗p- values < 0.001, strong statistical signifi-
cance. ∗∗0.01 < p ≤ 0.05, weak statistical significance.
iA standardized neuropathology protocol for neuritic plaque score developed by the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) [14].
iiCriteria utilized, previously published [12, 44], a staging scheme for neurofibrillary tangles (NFTs) described by Braak and Braak which
encloses six stages: no NFTs, Braak stages I/II with NFTs predominantly in entorhinal cortex and closely related areas, stages III/IV with
NFTs more abundant in hippocampus and amygdala while extending slightly into association cortex, and stages V/VI with NFTs widely
distributed throughout the neocortex and also involving primary motor and sensory areas.
iiiThe third CDLB guidelines for diagnosis of Lewy-body Dementia with modified criteria. The load of Lewy-related pathology (LRP) was
semiquantitatively scored mild, moderate, severe and very severe and followed by the assignment of the type of LRP (none, brainstem-
predominant, limbic and diffuse neocortical), [43].
ivThe diagnosis of capillary amyloid- was determined using Congo red and confirmed by A immunohistochemistry, both analyzed in six
brain areas. The severity of capillary A was graded semi-quantitatively, and the severity of CAA was based on the percentage of affected
vessels [41].
vThe arteries of circulus Willis were inspected and opened at autopsy, and the degree of atherosclerosis was estimated based upon severity
of obstruction in artery. The classification was subdivided into four categories: none, mild, moderate and severe.
viLeft anterior descending, left circumflex and right coronary arteries were dissected at autopsy. The degree of coronary atherosclerosis was
estimated by the pathologist, and scored into four categories: none, mild, moderate and severe [42].
viiThe presence of TDP-43 immunoreactivity were assessed in the regions CA1 and subiculum, CA2, CA3-CA4 and granular layer of dentate
gyrus. TDP-43 immunoreactivity was determined as positive when NCIs were seen in the granular cell layer and CA1 + subiculum.
viiip62 immunoreactivity was scored as positive if seen positive NCIs in the granular cell layer of the dentate gyrus [45].
ixTau immunoreactivity was recorded mainly as neurofibrillary lesions and neuropil threads in the granular cell layer of the dentate gyrus,
sectors CA1-CA4 and subiculum.
itivity for TDP-43 and HPtau in the granular cell layer
of the fascia dentate in the hippocampus and modestly
with AD-associated neuritic plaques (CERAD score)
and vascular pathological variables, most notably
heart infarcts.
According to the literature, 10–25% of individu-
als older than 85 manifest HS in autopsy samples [4,
6, 7, 10, 11, 29, 30, 34]. The frequency of 15.6%
found in our study is in accordance with previous
studies on this age group [4, 11, 24, 30, 34]. Some of
the earlier studies have reported lower frequencies,
but these studies may have been influenced by their
investigation of younger cohorts [1, 2]. It is note-
worthy that the prevalence of HS has been shown
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to increase in the very elderly, particularly after 95
years [7, 17]. This age group was represented in our
study, where the mean age at death for HS subjects
was 93.22 years, and the oldest subject was 104.7
years old at the time of death. In addition, aware-
ness of HS has considerably increased during the last
ten years, which may have influenced the number of
diagnoses of HS, and may have had an impact on the
prevalence figures. Our study confirmed the strong
association with HS and dementia (p < 0,001) [1, 3,
4, 6, 9, 23, 32]. Only 2 out of 47 subjects with HS were
not demented (Table 2) and they both had unilateral
HS.
Most of the studies have reported male predomi-
nance for HS [11, 24, 30]. This is in contrast to our
population-based study, as we found women with HS
to be more prevalent (Table 2). The difference may
reflect the fact that in our population-based sample of
the very elderly, the great majority of study subjects
were women, whereas most of the other studies have
been based on younger populations and the propor-
tion of males has been much greater. This was also the
case in the previous community-based study, where
the mean age at death was almost 10 years younger
than in our study [30].
HS without comorbid neurodegenerative pathol-
ogy has been reported to occur in 0.4%–5.4% among
the individuals with HS [1, 5, 9, 30]. We found only
one (2.1%) such subject. In this study, HS without any
significant comorbid pathology was defined accord-
ing to the following criteria: Braak stage to be zero
and the CERAD score to be one, no neurofibrillary
tangles seen with HPtau antibody and no sign of Lewy
related pathology with -synuclein antibody. In the
previously reported studies the definition for HS with-
out any comorbid pathology has varied to some extent
[1, 2] allowing generally more relaxed criteria.
The borderline between HS and other diseases,
in particular AD, has been problematic. HS as part
of aging pathology has been reported to be found
in individuals with both low severity of AD and
high severity of AD pathology [35]. The prevalence
of HS pathology has been shown to increase dra-
matically beyond the age 95, while the prevalence
of AD- type pathology declines in that age group
[7, 17]. These findings might suggest that HS and
AD pathologies may occur independently from each
other, even though they affect the same part of the
hippocampus [7, 8]. In this study we found only a
weak association between HS and CERAD neuritic
plaque score, in accordance with previous studies,
where the co-occurrence of HS pathology with vari-
able CERAD neuritic plaque scores has been reported
[35]. More interestingly, we did not find any associ-
ation with Braak stage, but HPtau-immunopositivity
in the granular cell layer was associated with both
HS and granular cell TDP-43 pathology. This is in
agreement with a recent study, where dentate fas-
cia granule cells NFTs were frequently found in HS
cases, independent from Braak stage [23].
Laterality of HS has been reported in a few pub-
lished studies [11, 30]. In most studies hippocampus
is sampled only from one hemisphere, which is a
general approach in neuropathological practice, and
thus it is possible that the reported frequencies for
HS are underestimated. Here, we found 51.1% of
HS cases to be bilateral. Similar frequencies have
been seen in those few other studies, which have
sampled hippocampi from both hemispheres [11,
30]. Importantly, it should be routine practice in
neuropathological examination to sample both hip-
pocampi, in order to be able to make a reliable
diagnosis on demented subjects.
We found a strong association between HS and
immunopositivity of TDP-43 in the granular cell
layer of the fascia dentate, the CA1 and subiculum
(Table 2), in accord with previous studies [18–28].
In order to study, if TDP-43 positivity in the gran-
ular cell layer of could be an early marker of HS,
as suggested recently [23], we performed associa-
tion analyses using two different dependent variables:
1) HS defined by the HE finding and 2) TDP43-
positivity in the granular cell layer. We found very
similar results in both analyzes, in accordance with
the early marker hypothesis, even though TDP43-
positivity in the granular cells was clearly not specific
for HS. Recently, it has also been suggested that
TDP-43 pathology in HS could be a secondary
phenomenon reflecting pancerebral arteriolosclerosis
[23, 40]. This finding certainly needs to be replicated
by other studies. Although some vascular markers
were weakly associated with HS and TDP-43 posi-
tivity in the granular cells in our material, we do not
have data on brain arteriolosclerosis available in our
dataset, and thus this hypothesis could not be assessed
here.
There are several strengths and limitations in
our study. The Vantaa 85+ study is prospective
and population-based, and thus not influenced by
selection bias, commonly affecting epidemiological
studies. On the other hand, the study material is
relative small in size, which may have resulted in
lack of power in association analyses. Even though
hippocampi from both sides were investigated, we
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were not able to study the possible segmentality
of lesions [46], as the hippocampi samples were
collected only at the level of the lateral geniculate
body. We managed to use the right side hippocampal
PEG- embedded tissue blocks (being PEG-embedded
for 14–24 years) for HE- and immunohistochemi-
cal stainings, after reprocessing of those blocks into
FFPE- blocks, which are easier to handle. To the
best of our knowledge, this procedure has not been
reported before. This method could be useful for other
research groups having historical PEG-embedded
material.
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